Build an AI Oncology Imaging Suite

1. 1

   Understand the longitudinal, oncology-specific model

   Unlike single-scan detection, an oncology imaging suite quantifies tumor burden and tracks how it changes across serial CT and MRI scans over time, which is what oncology actually needs to judge treatment response. The value is in the trend across scans, not one image. This is a distinct category built around monitoring, not acute triage.

2. 2

   Solve consistent measurement across time

   The hard technical problem is registering and comparing scans from different dates (and sometimes scanners) so measurements are consistent and changes are real, not artifacts of positioning or protocol. Reliable segmentation and quantification across time is the core capability. Inconsistent measurement makes the trend meaningless, so this is where the engineering effort concentrates.

3. 3

   Validate against oncology response criteria

   Tumor assessment uses established response criteria (such as RECIST) in care and trials, so your quantification must align with and add value to those standards. Validate against clinical outcomes and criteria, and clear the appropriate FDA pathway for your claims. Oncology credibility depends on measuring what oncologists and trialists trust.

4. 4

   Integrate into cancer-center and trial workflows

   Deploy into oncology imaging workflows and, importantly, clinical-trial imaging, where consistent, auditable tumor measurement across time is essential and well-funded. Integration with PACS and oncology systems, plus trial-grade auditability, opens the highest-value uses. Trials are a distinct, lucrative buyer with strict requirements.

5. 5

   Monetize longitudinal monitoring

   Revenue comes from ongoing monitoring across a patient's treatment course and from clinical-trial endpoint measurement, not a one-time read, which is a more recurring value than single-scan tools. Price around the monitoring relationship and trial contracts. This recurring, longitudinal value is the model's advantage.

6. 6

   Distinguish from detection and risk tools

   This is not acute-finding triage or forward-looking risk prediction; it is longitudinal quantification of known disease over time. The buyer (cancer centers, oncology practices, trial sponsors) and the value (response assessment) are specific. Precision about the oncology monitoring use case defines the business.

Do not take our word for the money. Put your own numbers in and see what this idea has to earn before it works. Free, instant, no account needed.